Acomplia rimonabant regulatory update

FDA accepted for filing an NDA for Acomplia rimonabant to manage cardiovascular risk factors. The PDUFA date is in the first quarter of 2006. An MAA for the cannabinoid CB1 receptor antagonist is als...